|
[1]
|
TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
Journal of Clinical Oncology,
2022
DOI:10.1200/JCO.21.02506
|
|
|
|
|
[2]
|
The Synthetic Curcumin Analog HO-3867 Rescues Suppression of PLAC1 Expression in Ovarian Cancer Cells
Pharmaceuticals,
2021
DOI:10.3390/ph14090942
|
|
|
|
|
[3]
|
TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses
International Journal of Gynecologic Cancer,
2019
DOI:10.1136/ijgc-2018-000087
|
|
|
|
|
[4]
|
Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)
International Journal of Molecular Sciences,
2018
DOI:10.3390/ijms19051510
|
|
|
|
|
[5]
|
The miRNA as human cell gene activity regulator after ionizing radiation
Russian Journal of Genetics,
2017
DOI:10.1134/S1022795417020077
|
|
|
|
|
[6]
|
Precision Molecular Pathology of Uterine Cancer
Molecular Pathology Library,
2017
DOI:10.1007/978-3-319-57985-6_5
|
|
|
|
|
[7]
|
Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer
Oncology Letters,
2017
DOI:10.3892/ol.2017.5582
|
|
|
|
|
[8]
|
Effect of vascular endothelial growth factor siRNA and wild-type p53 co-expressing plasmid in MDA-MB-231 cells
Molecular Medicine Reports,
2016
DOI:10.3892/mmr.2015.4571
|
|
|
|
|
[9]
|
Confronting the Care Delivery Challenges Arising from Precision Medicine
Frontiers in Oncology,
2016
DOI:10.3389/fonc.2016.00106
|
|
|
|
|
[10]
|
microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma
Oncotarget,
2016
DOI:10.18632/oncotarget.7666
|
|
|
|